Anji Pharma (“Anji”), invested and incubated by Viva BioInnovator, announced that ANJ900 (delayed-release metformin)’s phase III clinical trials in patients with Type 2 diabetes (T2D), including those with varying stages of renal disease, has been approved by the China National Drug Administration's Drug Evaluation Center (CDE) recently, to carry out bridge tests and key clinical trials. This is another major progress of the Anj900 after the launch of the global key phase III clinical trial of Anj900 back in May.